Al-Dadah Ashraf, Omran Jad, Nusair Maen B, Dellsperger Kevin C
Cardiovascular Medicine Division, University of Missouri-Columbia, Columbia, Missouri 65212, USA.
Adv Perit Dial. 2012;28:56-9.
In their broad spectrum, cardiovascular diseases are, collectively, the major cause of death in patients on dialysis. The population of patients treated with peritoneal dialysis and hemodialysis are not only subject to the traditional risk factors for heart disease, but also to certain uremia-associated risk factors that are unique in this population. In the dialysis population, data regarding the effectiveness of routine pharmacologic and procedural interventions on cardiovascular outcomes are limited. Most dialysis patients are excluded from clinical trials, and so data from randomized controlled trials investigating outcomes in patients undergoing peritoneal dialysis or hemodialysis are almost absent. In this review, we discuss some of the major cardiovascular problems in the dialysis population, the impact of those problems on survival, and when data are available, the impact of therapeutic strategies.
在其广泛范围内,心血管疾病总体上是透析患者的主要死因。接受腹膜透析和血液透析治疗的患者群体不仅面临心脏病的传统风险因素,还面临该群体特有的某些与尿毒症相关的风险因素。在透析人群中,关于常规药物和程序干预对心血管结局有效性的数据有限。大多数透析患者被排除在临床试验之外,因此几乎没有关于腹膜透析或血液透析患者结局的随机对照试验数据。在本综述中,我们讨论了透析人群中的一些主要心血管问题、这些问题对生存的影响,以及在有数据时治疗策略的影响。